Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you take diazepam regularly and are considering Mounjaro for weight management, the practical question is straightforward: does one affect the other? Mounjaro (tirzepatide) slows gastric emptying, which can alter how quickly oral medicines are absorbed — and for any medicine with a narrow therapeutic window or time-sensitive dosing, that matters. Diazepam is a prescription-only benzodiazepine; Mounjaro is a prescription-only dual GIP/GLP-1 receptor agonist. Both require clinical oversight, and combining them is a conversation for the prescriber who knows your full picture, not a decision to make from a forum thread. This page sets out the pharmacological facts, what current guidance says, and what to raise before you start.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You're already managing anxiety, muscle spasm or another condition with diazepam (taken daily, or kept for acute use) and weight management has come up as a clinical priority. The question in your head is a sensible one: will these two medicines get in each other's way?
Start with what Mounjaro actually does to your gut. Tirzepatide activates both GIP and GLP-1 receptors, which slows the rate at which food (and anything you've swallowed) moves from the stomach into the small intestine. For oral medicines, this delay can shift the timing of peak plasma concentration. It does not automatically reduce how much of a medicine eventually reaches the bloodstream, but it can shift when that peak arrives. For diazepam, which is reliably absorbed but not time-critical in the way a narrow-therapeutic-index drug like warfarin is, this effect is less alarming than it sounds. That said, if your diazepam dose has been calibrated on the basis of a predictable absorption pattern, a change in that pattern is worth flagging.
The Mounjaro overview at nume covers the medicine's mechanism in full if you want the broader context before reading on.
Diazepam is a central nervous system depressant. Among the side effects that tirzepatide commonly produces (especially in the early weeks of treatment) are fatigue, dizziness and occasional headaches, as documented on the NHS tirzepatide medicine page. Neither of these is a direct CNS depressant in the way diazepam is, but the lived experience of someone managing diazepam-related drowsiness who then adds a medicine that causes tiredness is one a prescriber needs to account for.
This is not a reason to avoid Mounjaro. It is a reason to be specific with your prescriber: how much diazepam, how often, for what indication, and what your baseline fatigue looks like. A real clinician reviews every nume consultation personally (your answers are read by a GPhC-registered Independent Prescriber, not filtered through software) so the detail you provide shapes the decision.
If you use diazepam only occasionally (for example, for flight anxiety, or a short course around a procedure), the timing relative to your Mounjaro injection day is worth raising. That's exactly the sort of practical question that comes up in consultations — a bit like thinking through payday orders or bank holiday delivery windows: the detail is mundane but it matters to get right.
Tirzepatide is not metabolised through the CYP450 enzyme system in any meaningful way. Diazepam is primarily metabolised by CYP2C19 and CYP3A4 in the liver. Because the two medicines do not compete at the same metabolic sites, the classic definition of a pharmacokinetic drug–drug interaction does not apply here in the way it would for, say, a CYP3A4 inhibitor taken alongside diazepam.
The Mounjaro Summary of Product Characteristics (available via the electronic Medicines Compendium (eMC)) notes the gastric-emptying effect and advises caution with oral medicines where timing-dependent absorption matters clinically. Diazepam sits in a lower-risk category on that spectrum than anticoagulants or certain anticonvulsants, but it is not absent from the conversation. Pharmacodynamic overlap (the additive sedation and CNS-depression picture) deserves more attention than the enzyme question for most patients in this situation.
For those also managing anxiety or related conditions, the page on Mounjaro and related conditions touches on how GLP-1 treatment fits alongside other health priorities. And if benzodiazepine therapy sits alongside other medications such as clonazepam, the Mounjaro and clonazepam page covers that specific combination.
Before Mounjaro is initiated, your prescriber needs your complete medicines list. That means prescribed diazepam (dose, frequency, indication), any as-needed use, any other benzodiazepines, and any other CNS-active medicines including sleep aids or antihistamines you take for sedation. This is not bureaucratic box-ticking; it shapes both the clinical decision and the monitoring plan.
If you're already on Mounjaro and have been prescribed diazepam since starting, tell the prescribing team promptly. A clinical re-review of your situation, including any change in side-effect experience, is the right next step. You can read more about how Mounjaro treatment unfolds over time on the Mounjaro diary page, which covers real-world titration experiences.
The cost of weight management treatment is a separate conversation; the weight-loss treatments page sets that out clearly. What matters first is whether a clinical assessment confirms Mounjaro is appropriate for you given your full medication history. Speak to our prescribers, that's exactly what a free nume consultation is for.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.